0001193125-17-373165.txt : 20180119 0001193125-17-373165.hdr.sgml : 20180119 20171219105103 ACCESSION NUMBER: 0001193125-17-373165 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 545 PROMENADE DU CENTROPOLIS, SUITE 100 CITY: LAVAL STATE: A8 ZIP: H7T 0A3 BUSINESS PHONE: (450) 687-2262 MAIL ADDRESS: STREET 1: 545 PROMENADE DU CENTROPOLIS, SUITE 100 CITY: LAVAL STATE: A8 ZIP: H7T 0A3 CORRESP 1 filename1.htm CORRESP

The Benchmark Company, LLC

150 E 58th Street, 17th floor

New York, NY 10155

Dawson James Securities, Inc.

1 North Federal Highway, 5th Floor

Boca Raton, FL 33432

December 19, 2017

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Acasti Pharma, Inc. (the “Company”)

Registration Statement on Form F-1

File No. 333-220755

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as underwriter of the proposed offering, hereby joins the request of Acasti Pharma, Inc. that the effective date of the above-referenced Registration Statement on Form F-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Tuesday, December 19, 2017, or as soon as practicable thereafter.

In connection with this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that between December 15, 2017 and the date hereof, approximately 1,350 copies of the preliminary prospectus dated December 14, 2017 were distributed to underwriters, dealers, institutions and others.

The undersigned advise that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Sincerely,

 

The Benchmark Company, LLC

By:   /s/ John J. Borer
Name:   John J. Borer
Title:   Senior Managing Director

 

 

Dawson James Securities, Inc.
By:   /s/ Robert D. Keyser, Jr.
Name:   Robert D. Keyser, Jr.
Title:   CEO